

**ANGLO MEDICAL SCHEME
ANNEXURE C**

- 2.2.6.7 related to contact lens preparations;
- 2.2.6.8 related to the purchase of unregistered and off-label medications, unless authorised in respect of the Medicines and Related Substance Control Act 101 of 1965 and pre-authorised according to Scheme protocol, and proprietary preparations;
- 2.2.6.9 related to the purchase of prescription medicines not prescribed by a medical practitioner or other person who is legally entitled to prescribe medicine, except for medicines purchased in accordance with the pharmacist advised therapy (PAT) benefit, reflected in Annexures B1 and B2;
- 2.2.6.10 related to anabolic steroids, aphrodisiacs, tonics and homemade medicines;
- 2.2.6.11 related to the treatment of slimming products used to treat or prevent obesity, provided that this exclusion shall not apply to medicine prescribed for bariatric surgery under Rule 2.2.1 or to GLP-1 receptor agonist therapies approved and prescribed for the treatment of obesity and weight management;
- 2.2.6.12 related to bandages and dressings;
- 2.2.6.13 related to the general food/nutritional supplements, including all baby food and milk supplements,

**ANGLO MEDICAL SCHEME
ANNEXURE C**

except where clinically indicated in managed care protocols;

2.2.6.14 related to soaps, shampoos, cosmetic preparations medicated or otherwise; emollients, moisturisers, sunscreens and other similar topical applications;

2.2.6.15 related to preparations not easily classified or without NAPPI codes; and

2.2.6.16 for frail care for Standard Care Plan members.

3. Specific limitations of benefits and general exclusions applicable to the Value Care Plan inclusive of the aforementioned points

3.1 all services not obtained through a Prime Cure designated service provider, or referrals not pre-authorised, or not provided in terms of the Prime Cure protocol subject to PMB;

3.2 facility fees;

3.3 the following medicines are specifically excluded from cover in respect of CDL conditions -

3.3.1 Erythropoietin (unless the beneficiary is eligible for renal transplantation);

3.3.2 Infliximab and related biologics for inflammatory bowel disease and rheumatoid arthritis;